According to a new study, scientists have shown that one oral dose of azithromycin (a common antibiotic) can reduce the risk of maternal sepsis and death in vaginally-born women.
The study found that maternal infection increases the risk for neonatal sepsis. This is responsible for 16% of all newborn deaths.
According to the study, maternal infections and sepsis are the leading causes of maternal death worldwide.
According to the study, 10 percent of maternal deaths result from infections occurring shortly before, during, or after birth.
The results of the Azithromycin Preventive in Labor Use Study (or A-PLUS) trial, led by UAB investigators, US, augmented information from earlier UAB-led trials that showed azithromycin before cesarean delivery decreased maternal infections.
According to the study, the multi-country, randomized trial was carried out at eight locations in seven low- or middle-income countries in Africa and Latin America.
Professor in the UAB Department of Obstetrics and Gynology, Alan Tita said that "the World Health Organization and other organizations have prioritized reducing maternal mortality,"
There were no studies that confirmed the effectiveness of azithromycin in vaginal delivery (which is the most popular method of delivery). Tita stated that they wanted to find a low cost intervention that could be used worldwide to address this problem.
The study found that more than 29,000 women were randomly assigned to an active or placebo group between September 2020 and August 2022.
The study stated that the azithromycin was given to the active group in a single dose of 2 grams.
.jpg)
.jpg)
0 टिप्पणियाँ